Welcome to our dedicated page for United Therapeutics news (Ticker: UTHR), a resource for investors and traders seeking the latest updates and insights on United Therapeutics stock.
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology and pharmaceutical company focused on therapies for pulmonary arterial hypertension, pulmonary hypertension associated with interstitial lung disease, and other serious conditions, as well as technologies to expand the availability of transplantable organs. This news page aggregates company announcements, clinical updates, financial disclosures, and conference presentations related to UTHR.
Recent news highlights include detailed results from the TETON-2 phase 3 study of nebulized Tyvaso (treprostinil) Inhalation Solution in idiopathic pulmonary fibrosis, where United Therapeutics reported that the trial met its primary efficacy endpoint and achieved statistically significant improvements in several secondary endpoints. The company has also announced the first clinical xenotransplantation of its investigational UKidney xenokidney in the EXPAND study for patients with end-stage renal disease, reflecting its stated public benefit purpose of expanding access to transplantable organs.
Investors and followers of UTHR can review press releases on quarterly financial results, including product-level revenue disclosures for Tyvaso DPI, nebulized Tyvaso, Remodulin, Orenitram, Unituxin, Adcirca, and other items. Additional updates cover accelerated share repurchase agreements, stock incentive plan changes, and participation in major investor conferences hosted by firms such as J.P. Morgan, UBS, Jefferies, and Bernstein.
For those tracking developments in pulmonary hypertension, interstitial lung disease, xenotransplantation, and the company’s public benefit corporation activities, this news feed offers a centralized view of United Therapeutics’ clinical data presentations, regulatory milestones, and corporate actions. Bookmark this page to quickly access new UTHR press releases and related market-moving information as they are published.
United Therapeutics (UTHR) has released its 2024 Corporate Responsibility and Public Benefit Report, highlighting progress towards its public benefit goals in FY 2023. As a public benefit , UTHR focuses on developing novel pharmaceutical therapies and technologies to expand transplantable organ availability. Key achievements include:
- Serving over 14,500 patients, with 100+ benefiting from ex vivo lung perfusion service
- Patient assistance program helping 32,000+ patients access treatments since 2010
- 90%+ employee satisfaction as a Great Place to Work since 2018
- 26% of properties LEED certified, including LEED Platinum Unisphere building
- Maintaining 7-MW capacity onsite solar fields
The company emphasizes balancing patient needs, employee welfare, and environmental sustainability in its operations.
United Therapeutics (Nasdaq: UTHR), a public benefit , has announced its participation in two upcoming investor conferences. Michael Benkowitz, President and COO, will present at the Morgan Stanley 22nd Annual Global Healthcare Conference in New York City on September 4, 2024. James Edgemond, CFO and Treasurer, will present at the 2024 Wells Fargo Healthcare Conference in Boston on September 5, 2024.
Both sessions will be accessible via live webcasts on the company's website, with archived recordings available for 90 days. United Therapeutics is known for its innovative approach to addressing unmet medical needs and its unique status as the first publicly-traded biotech or pharmaceutical company to become a public benefit
United Therapeutics (UTHR) reported strong financial results for Q2 2024, with total revenues growing 20% year-over-year to $714.9 million. Key highlights include:
- Net income increased 7% to $278.1 million
- Diluted EPS rose 12% to $5.85
- Tyvaso revenues grew 25% to $398.2 million
- Remodulin revenues increased 16% to $147.3 million
The company attributed its growth to continued traction for Tyvaso in pulmonary hypertension associated with interstitial lung disease, along with strong performance of other products. United Therapeutics also announced a $1 billion accelerated share repurchase program, with final settlement expected in Q3 2024.
United Therapeutics (Nasdaq: UTHR) has announced that it will release its second quarter 2024 financial results before the market opens on Wednesday, July 31, 2024. A press release detailing the quarterly results will be issued at approximately 6:30 a.m. Eastern Time. The company will host a public webcast at 9:00 a.m. Eastern Time on the same day, accessible via their website. A rebroadcast of the webcast will be available for one year.
United Therapeutics is a publicly-traded biotech company that has taken the form of a public benefit (PBC). Their mission focuses on innovating for unmet medical needs and developing novel pharmaceutical therapies and technologies to expand the availability of transplantable organs.
United Therapeutics (Nasdaq: UTHR) announced the full enrollment of the TETON 2 study, evaluating Tyvaso® (treprostinil) inhalation solution for idiopathic pulmonary fibrosis (IPF). The study enrolled 597 patients outside the U.S. and Canada and is part of a global program assessing inhaled treprostinil in IPF and progressive pulmonary fibrosis (PPF). Top-line data is expected in the second half of 2025. The TETON program is inspired by favorable outcomes from the INCREASE study, which showed significant improvements in forced vital capacity (FVC) for IPF patients using nebulized Tyvaso. United Therapeutics aims to use these studies to seek FDA approval for Tyvaso DPI to treat IPF and PPF.
United Therapeutics (Nasdaq: UTHR) has elected Jan Malcolm, former Minnesota Commissioner of Health, to its Board of Directors. She was elected by shareholders during the annual meeting on June 26, 2024. Malcolm has a distinguished career in health policy, public health, and healthcare finance, highlighted by her leadership during the COVID-19 pandemic in Minnesota and her recognition by the American Medical Association with the AMA Award for Outstanding Government Service. Her experience includes roles at Allina Health and Courage Center. Malcolm will contribute to United Therapeutics' mission to address unmet medical needs, particularly in the area of end-stage organ diseases.
United Therapeutics (Nasdaq: UTHR) will present at the Goldman Sachs 45th Annual Global Healthcare Conference. Patrick Poisson, Executive Vice President, Technical Operations, will provide an overview and update on the company's operations during a fireside chat session. This session is scheduled for Wednesday, June 12, 2024, from 4:00 p.m. to 4:35 p.m. Eastern Daylight Time in Miami Beach, Florida. The session will be accessible via a live webcast on United Therapeutics' website and will be archived for 90 days post-event. United Therapeutics, a public benefit , focuses on developing novel pharmaceutical therapies and technologies to expand the availability of transplantable organs.
United Therapeutics reported strong financial results for the first quarter of 2024, with total revenues growing by 34 percent year-over-year to $677.7 million. The company's net income also increased by 27 percent, demonstrating its solid commercial foundation and growth potential. Key highlights include the implementation of a $1 billion accelerated share repurchase program, showcasing confidence in the company's future prospects.
Summary not available.
Summary not available.